Figure 7.

Soluble OM-MOG retains and activates Ly6C^hi CCR2⁺ monocytes in the skin DLN: (A) Proportions of Ly6C^hiCCR2⁺ monocytes (left graph), and Ly6C^hiCCR2⁺ monocytes expressing MHCII (right graph) in blood, spleen and draining inguinal LN (DLN) of EAE mice 3 h after a single therapeutic i.d. injection of vehicle (EAE control) or OM-MOG (n=4/group). (B) Proportions of Ly6C^hiCCR2⁺ monocytes expressing MHCII in the DLN of EAE mice 3 h and 24 h after a single therapeutic i.d. injection of vehicle (EAE control) or OM-MOG (n=3/group). (C) Proportions of PD-L1-producing CD11b⁺CD11c^-, CD11b⁺CD11c⁺ (myeloid DC), CD11b^-CD11c⁺ (DC) and CD11b⁺CD11c^-Ly6C^hi cells in the DLN of EAE mice 3 h and 24 h after a single therapeutic i.d. injection of vehicle (EAE control) or OM-MOG, as in B (n=3/group). Data and statistical analysis are from one (B, C) or one of 2 independent experiments (A). Statistical significance is shown after comparisons between groups using Mann-Whitney test (A), or one-way ANOVA followed by Tukey’s post hoc test (B, C) (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).